ORR 84%!复星医药MEK抑制剂“芦沃美替尼”新适应症拟优先审评

医药魔方Info
Nov 04

11月4日,CDE网站显示,复星医药自主研发的芦沃美替尼(曾用名:复迈替尼,研发代号:FCN-159)的新适应症拟纳入优先审评,用于2岁及2岁以上朗格汉斯细胞组织细胞增生症(LCH)儿童患者。LCH是一种以丝裂原活化蛋白激酶信号通路激活为主要分子特征的克隆性血液系统肿瘤,可累及全身各器官及系统,临床表现多样。芦沃美替尼是复星医药自主研发的创新型小分子MEK1/2选择性抑制剂,通过阻断MAPK信号...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10